Roche announced today that the European Commission has approved its innovative drug Mircera to treat anaemia associated with chronic kidney disease (CKD). The approval of Mircera results in a single ...

IN 2015 VIFOR PHARMA (FORMERLY A COMPANY OF GALENICA GROUP) ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH ROCHE FOR THE COMMERCIALISATION OF ITS MEDICINE MIRCERA ® in the US. MIRCERA ® IS A ...

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy polyethylene glycol-epoetin beta) for the treatment of anaemia associated with chronic kidney ...

-- Findings Illustrate Role of Innovative New Treatment in Population Most Affected by Chronic Kidney Disease A new Roche Phase III analysis shows once-monthly MIRCERA, a continuous erythropoietin ...

maintained Hb levels as effectively as more frequently-dosed ESAs, in patients with the lowest baseline Hb who are difficult to treat. - In the correction studies, the mean baseline low Hb in the ...

New data for Roche’s anaemia drug Mircera confirm that the drug can raise haemoglobin levels in the blood with twice-monthly dosing, suggesting it will mount a strong challenge to current treatments ...

Researchers have successfully developed a new electrophoretic method for detecting MIRCERA and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced ...

The approval was based on an open-label, multiple dose, multicenter, dose-finding study in 64 pediatric patients with CKD who were on hemodialysis and who had stable hemoglobin levels while previously ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Mircera for the treatment of pediatric patients 5 to 17 years of age on hemodialysis who are ...

who are converted to treatment with MIRCERA. The safety and efficacy of MIRCERA therapy in other indications has not been established. When approved by the European Commission, MIRCERA will become the ...

Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains haemoglobin levels in chronic kidney disease ...

Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA® and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically ...